within Pharmacolibrary.Drugs.ATC.L;

model L03AB61
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0016666666666666668,
    adminDuration  = 600,
    adminMass      = 180 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.008,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L03AB61</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Peginterferon alfa-2a is a pegylated form of interferon alfa-2a, an immunomodulatory agent used primarily in the treatment of chronic hepatitis B and C infections, often in combination with antiviral medications such as ribavirin. Peginterferon alfa-2a is still used, but its clinical use has declined with the advent of direct-acting antivirals.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters have been evaluated mainly in adult patients with chronic hepatitis C, both male and female, generally aged 18–65 years, with or without cirrhosis, receiving subcutaneous weekly administration.</p><h4>References</h4><ol><li><p>Sulkowski, M, et al., &amp; Yalamanchili, S (2005). Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. <i>Clinical pharmacology and therapeutics</i> 77(3) 214–224. DOI:<a href=&quot;https://doi.org/10.1016/j.clpt.2004.09.008&quot;>10.1016/j.clpt.2004.09.008</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15735615/&quot;>https://pubmed.ncbi.nlm.nih.gov/15735615</a></p></li><li><p>Fülöp, B, et al., &amp; Berg, T (2015). Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders. <i>Liver international : official journal of the International Association for the Study of the Liver</i> 35(10) 2275–2284. DOI:<a href=&quot;https://doi.org/10.1111/liv.12832&quot;>10.1111/liv.12832</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25801095/&quot;>https://pubmed.ncbi.nlm.nih.gov/25801095</a></p></li><li><p>Keating, GM, &amp; Curran, MP (2003). Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. <i>Drugs</i> 63(7) 701–730. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200363070-00008&quot;>10.2165/00003495-200363070-00008</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12656650/&quot;>https://pubmed.ncbi.nlm.nih.gov/12656650</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L03AB61;
